SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.

SG&A Efficiency: Walgreens vs. Merus N.V. Over a Decade

__timestampMerus N.V.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014385232717691000000
Thursday, January 1, 201583965621669000000
Friday, January 1, 2016447814523425000000
Sunday, January 1, 20171643232423618000000
Monday, January 1, 20181189087124638000000
Tuesday, January 1, 20193411000023183000000
Wednesday, January 1, 20203578100022836000000
Friday, January 1, 20214089600023798000000
Saturday, January 1, 20225220000024994000000
Sunday, January 1, 20235983600025479000000
Monday, January 1, 202428113000000
Loading chart...

In pursuit of knowledge

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Walgreens Boots Alliance, Inc., a global leader in retail pharmacy, and Merus N.V., a clinical-stage immuno-oncology company, present a fascinating study in contrasts. From 2014 to 2023, Walgreens consistently reported SG&A expenses in the range of $17.7 billion to $25.5 billion, reflecting its expansive operations. In contrast, Merus N.V.'s SG&A expenses grew from a modest $3.9 million to $59.8 million, showcasing a significant growth trajectory. This disparity highlights the different scales and operational strategies of these companies. While Walgreens' expenses are indicative of its vast retail network, Merus' increasing expenses suggest a strategic investment in growth and innovation. Notably, 2024 data for Merus is missing, leaving room for speculation on its future financial strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025